A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| c-JUN (1-79), GST tagged human | recombinant, expressed in E. coli, ?50% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. |  |
| C-Jun-amino-terminal kinase-interacting protein 2 (683-692) | C-Jun-amino-terminal kinase-interacting protein 2 (683-692) is a peptide fragment of C-Jun-amino-terminal kinase-interacting protein 2. C-Jun N-terminal kinases (JNKs) are a family of protein kinases that play a central role in stress signaling pathways implicated in gene expression, neuronal plasticity, regeneration, cell death, and regulation of cellular senescence. It can be used in Ovarian carcinoma research. |  |
| c-Jun Control Cell Extract, Non-Phosphorylated | c-Jun Control Cell Extract, Non-Phosphorylated. Group: Molecular Biology. Pack Sizes: 1x150ul. US Biological Life Sciences. |  Worldwide |
| c-Jun Control Cell Extract, Phosphorylated | c-Jun Control Cell Extract, Phosphorylated. Group: Molecular Biology. Pack Sizes: 1x150ul. US Biological Life Sciences. | Worldwide |
| c-Jun Control Cell Extracts | C-Jun is a component of the transcription factor AP-1 that binds and activates transcription at TRE/AP-1 elements. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 (1,2). Extracellular signals including growth factors, transforming oncoproteins and UV irradiation stimulate phosphorylation of c-Jun at Ser63/73 and activate c-Jun dependent transcription. Mutation of Ser63/73 renders c-Jun nonresponsive to mitogenic and stress induced signaling pathways. The MAP kinase homologue, SAPK/JNK, binds to the N-terminal region of c-Jun and phosphorylates c-Jun at Ser63/73. In addition, the activity of SAPK/JNK is stimulated by the same signals that activate c-Jun (3,4). Nonphosphorylated c-Jun (Ser63) II Cell Extracts: Total cell extracts from NIH/3T3 cells, prepared without treatment, serve as a negative control. Group: Biologicals. Grades: Lysate. Pack Sizes: 10Blots. US Biological Life Sciences. | Worldwide |
| c-JUN peptide | c-JUN peptide is a JNK/c-Jun interaction inhibitor. Synonyms: (2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid. Grade: >98%. CAS No. 610273-01-3. Molecular formula: C121H210N36O34S. Mole weight: 2745.24. | |
| C-jun, proto oncogene human | recombinant, expressed in insect cells, ?80% (SDS-PAGE). Group: Fluorescence/luminescence spectroscopy. | |
| CK0106023 | CK0106023 was specific inhibitor of KSP. In tumor-bearing mice, CK0106023 exhibited antitumor activity comparable to or exceeding that of paclitaxel and caused the formation of monopolar mitotic figures identical to those produced in cultured cells. KSP was most abundant in proliferating human tissues and was absent from cultured postmitotic neurons. Synonyms: CK 0106023; CK-0106023; N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)-4-bromo-N-(3-(dimethylamino)propyl)benzamide. CAS No. 336115-72-1. Molecular formula: C30H32BrClN4O2. Mole weight: 595.97. | |
| CK-119 | CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly through the inhibition of DNA and RNA syntheses but not protein synthesis. Synonyms: diethyl 6-[(4-chlorophenyl)methyl]-1,4-dimethyl-5-oxopyridazino[4,5-c]pyridazine-3,4-dicarboxylate; CK-119; CK119; CK 119; UNII-AL53N923EI; GC-6119; GC 6119; GC6119. Grade: >98%. CAS No. 197917-10-5. Molecular formula: C21H23ClN4O5. Mole weight: 446.88. | |
| CK1 ? 1, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1?1, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1 ? 2, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1 ? 3, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK 17 | CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation. Synonyms: CK 17; CK17; CK-17; 5-Bromotetrahydro-5-methyl-3-phenyl-2-(phenylimino)-4H-1,3-thiazin-4-one. Grade: 98%. CAS No. 86727-00-6. Molecular formula: C17H15BrN2OS. Mole weight: 375.29. | |
| CK 1827452 | CK-1827452 is a diaryl urea compound that increases cardiac myosin ATPase activity in a dose-dependent manner that is selective for cardiac myosin over non-cardiac myosins. It promotes myosin cross-bridge formation, increasing the duration and amount of myocyte contraction without affecting intracellular calcium or cAMP. It has been shown to increase cardiac efficiency in clinical studies of patients with chronic heart failure. Group: Biochemicals. Alternative Names: Methyl 4- [ [2-Fluoro-3- [N'- (6-methylpyridin-3-yl) ureido] phenyl] methyl] piperazine-1-carboxylate; 4- [ [2-Fluoro-3- [ [ [ (6-methyl-3-pyridinyl) amino] carbonyl] amino] phenyl] methyl] -1-piperazinecarboxylic Acid Methyl Ester; Omecamtiv Mecarbil. Grades: Highly Purified. CAS No. 873697-71-3. Pack Sizes: 5mg, 10mg. Molecular Formula: C??H??FN?O?, Molecular Weight: 401.43. US Biological Life Sciences. | Worldwide |
| CK1 ?, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1-IN-1 | CK1-IN-1 is an inhibitor of casein kinase 1 (CK1) with IC50 of 15 nM, 16 nM and 73 nM for CK1δ, CK1ε and p38α MAPK, respectively. Synonyms: PUN51207; Compound 1C. CAS No. 1784751-20-7. Molecular formula: C24H15F2N3. Mole weight: 383.39. | |
| CK1-IN-3 | CK1-IN-3 is a casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases. Synonyms: N-(6-Methoxybenzo[d]thiazol-2-yl)-2-(2-methoxyphenyl)acetamide; N-[(2E)-6-methoxy-1,3-benzothiazol-2(3H)-ylidene]-2-(2-methoxyphenyl)acetamide. CAS No. 349438-74-0. Molecular formula: C17H16N2O3S. Mole weight: 328.39. | |
| CK-2130 | CK-2130 is a bio-active imidazolone developed to treat congestive heart failure. It inhibited human platelet aggregation produced by adenosine diphosphate and sodium arachidonate. Uses: Ck-2130 is used to treat congestive heart failure. Synonyms: CK 2130; CK-2130; CK2130. 4-Ethyl-1,3-dihydro-5-[4-[(2-methyl-1H-imidazol)-1-yl]benzoyl]-2H-imidazol-2-one; CK2130; 4-Ethyl-5-[4-(2-methylimidazol-1-yl)benzoyl]-1,3-dihydroimidazol-2-one. Grade: >98 %. CAS No. 101184-07-0. Molecular formula: C16H16N4O2. Mole weight: 296.33. | |
| CK2?1, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK-2289 | CK-2289 is an type III cyclic 3'5'-adenosine monophosphate phosphodiesterase inhibitor. It may be used in the treatment of congestive heart failure. Uses: Ck-2289 may be used in the treatment of congestive heart failure. Synonyms: CK 2289; CK-2289; CK2289. 4-[4-(1H-Imidazol-1-yl)benzoyl]-5-ethyl-1H-imidazol-2(3H)-one; 4-Ethyl-5-[4-(1H-imidazol-1-yl)benzoyl]-1H-imidazol-2(3H)-one; 2H-Imidazol-2-one,4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-; 4-Ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one. Grade: >98 %. CAS No. 101183-99-7. Molecular formula: C15H14N4O2. Mole weight: 282.30. | |
| CK2 ? 2, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK2/ERK8-IN-1 | CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) and ERK8. It also binds to Pim-1, HIPK2, and DYRK1A. CK2/ERK8-IN-1 induces apoptosis in Jurkat cells when used at concentrations ranging from 10 to 50 μM. Synonyms: TMCB; 4,5,6,7-Tetrabromo-2-(dimethylamino)-1H-benzimidazole-1-acetic acid. Grade: ≥99%. CAS No. 1085822-09-8. Molecular formula: C11H9Br4N3O2. Mole weight: 534.82. | |
| CK2/ERK8-IN-1 | CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 μM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 ?M. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 μM, 15.25 μM, and 11.9 μM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1085822-09-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-135906. |  |
| CK2 inhibitor 10 | CK2 inhibitor 10 is a potent and ATP-competitive inhibitor of protein kinase (CK2; IC50 values of 32 nM and 46 nM for CK2α and CK2α' respectively). Compound 10 dose-dependently inhibits the kinases. It exhibits potent cytotoxicity towards lung cancer cells A549, colorectal cancer cells HCT-116, and breast cancer cells MCF-7. Synonyms: CK2-IN-3b; 4-(2-(4-methoxybenzamido)thiazol-5-yl)benzoic acid. Grade: 99%. CAS No. 1361229-76-6. Molecular formula: C18H14N2O4S. Mole weight: 354.38. | |
| CK2 inhibitor 2 | CK2 inhibitor 2 is a potent, selective and orally active CK2 inhibitor with favorable antiproliferative and antitumor activities. It has high selectivity for Clk2 (IC50 = 32.69 nM)/CK2 (IC50 = 0.66 nM). Synonyms: 5-(3-chlorophenylamino)-N-(2-hydroxyethyl)benzo[c][2,6]naphthyridine-8-carboxamide; Benzo[c][2,6]naphthyridine-8-carboxamide, 5-[(3-chlorophenyl)amino]-N-(2-hydroxyethyl)-. Grade: ≥98%. CAS No. 2641079-92-5. Molecular formula: C21H17ClN4O2. Mole weight: 392.84. | |
| CK2/PIM1-IN-1 | CK2/PIM1-IN-1 is a CK2 and PIM1 inhibitor, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CAS No. 292640-28-9. Molecular formula: C15H9NO4S2. Mole weight: 331.37. | |
| CK 3197 | CK 3197 is a Phosphoric diester hydrolase inhibitor originated by Bayer HealthCare Pharmaceuticals. CK 3197 has hemodynamic and myocardial energetic effects. In Jan 2007, preclinical for Heart failure in USA was discontinued. Uses: Heart failure. Synonyms: CK 3197; CK-3197; CK3197. 1-benzoyl-5-(4-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)benzoyl)-4-ethyl-1,3-dihydro-2H-Imidazol-2-one. Grade: 98%. CAS No. 132523-92-3. Molecular formula: C23H22N4O3. Mole weight: 402.45. | |
| CK-636 | CK-636 is an Arp2/3 complex inhibitor. CK-636 binds between Arp2 and Arp3, where it appears to block movement of Arp2 and Arp3 into their active conformation. CK-636 inserts into the hydrophobic core of Arp3 and alters its conformation. Synonyms: CK636; CK 636; CK-636; CK0944636; CK-0944636; CK 0944636. CAS No. 442632-72-6. Molecular formula: C16H16N2OS. Mole weight: 284.38. | |
| CK-636 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| CK-636 | CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC50 values of 4 ?M, 24 ?M and 32 ?M for human, fission yeast and bovine, respectively. CK636 blocks cell migration. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CK-0944636. CAS No. 442632-72-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15892. | |
| CK 666 | CK 666. Group: Biochemicals. Grades: Purified. CAS No. 442633-00-3. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| CK-666 | CK 666 has been found to be an inhibitor of the Arp2/3 complex and could also restrain actin polymerization. Synonyms: 442633-00-3; 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide; CK-666; CK 666; CK-0944666; 2-Fluoro-N-(2-(2-methyl-1H-indol-3-yl)ethyl)benzamide; 3ukr; UXRKUKRXVWJFER-UHFFFAOYSA-N; Oprea1_850670; SCHEMBL3382638; CHEBI:78843; DTXSID70343330; 2-Fluoro-N-[2-(2-methyl-1H-indol-3-yl)-ethyl]-benzamide; CK666; NSC821559; STK766770; AKOS001725056; CK 666?; NSC-821559; NCGC00370920-01; AS-82972; CK-666, >=98% (HPLC), powder; DA-62359; HY-16926; CS-0012973; F81773; SR-01000536526; SR-01000536526-1; Q27147993; Z1038843750; CKH. Grade: ≥99% by HPLC. CAS No. 442633-00-3. Molecular formula: C18H17FN2O. Mole weight: 296.34. | |
| CK-666 | CK-666 is a cell-permeable actin-related protein Arp2/3 complex inhibitor (IC50=12 ?M). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 442633-00-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-16926. | |
| CK-666 | ?98% (HPLC), powder. Group: Fluorescence/luminescence spectroscopy. | |
| CK 683A | CK 683A is a bio-active chemical,but no detailed information has been published yet. Synonyms: CK 683A; CK683A; CK-683A. 1,7-Bis((1-adamantyl)carbamylguanidino)-4-methyl-4-azaheptane. Grade: 98%. CAS No. 83539-21-3. Molecular formula: C32H57N9O5S. Mole weight: 679.92. | |
| CK7 | CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 507487-89-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103646. | |
| CK 869 | CK 869. Group: Biochemicals. Grades: Purified. CAS No. 388592-44-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| CK 869 | CK 869 has been found to inhibit actin polymerization as well as human and bovine actin-related protein 2/3 (Arp2/3) complex. Synonyms: CK-869; CK 869; CK869; CK-0157869; CK 0157869; CK0157869; 2-(3-Bromophenyl)-3-(2,4-dimethoxyphenyl)-4-thiazolidinone. Grade: ≥98% by HPLC. CAS No. 388592-44-7. Molecular formula: C17H16BrNO3S. Mole weight: 394.28. | |
| CK-869 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| CK-869 | CK-869 is an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor, with an IC50 of 7 ?M. Uses: Scientific research. Group: Signaling pathways. CAS No. 388592-44-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16927. | |
| CKD-516 | This active molecular is a tubulin polymerisation inhibitor which is applicated for solid cancer treatment. CKD-516 disruptes tubulin of the endothelial cytoskeleton selectively. In Jun 2012, a South Korea company, Chong Kun Dang initiated enrolment in a phase I trial for solid tumours treatment in South Korea. In Dec 2014, Phase-I clinical trials in Solid tumours in South Korea was on going. Uses: Solid tumours. Synonyms: CKD-516 HCl; CKD 516 HCl; CKD516 HCl; (2S)-2-amino-3-methyl-N-[4-[3-(1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol-2-yl]butanamide; hydrochloride; 1188371-47-2 (free base). Grade: 98%. CAS No. 1188371-47-2. Molecular formula: C26H28N6O5S. Mole weight: 536.6. | |
| CKD-516 HCl | CKD-516 is tubulin inhibitor for solid cancer, which was initiated phase 1 trial in Korea in 2010. CKD-516 selectively disrupted tubulin component of the endothelial cytoskeleton. Serial DCE-MRI showed a significant decrease in K-trans and IAUGC parameters from baseline at 4 h (39.9 % in K-trans; -45.0 % in IAUGC) and at 24 h (-32.2 % in K-trans; -36.5 % in IAUGC), and a significant recovery at 48 h (22.9 % in K-trans; 34.8 % in IAUGC) following administration of CKD-516 at a 0.7-mg/kg dose. When the tumors were stratified according to the initial K-trans value of 0.1, tumors with a high K-trans?>?0.1 which was indicative of having well-developed pre-existing vessels, showed greater reduction in K-trans and IAUGC values. On histologic examination, the degree of necrosis of treated tumors was significantly greater than that of untreated tumors. In summary, CKD-516 is an effective VDA which results in rapid vascular shutdown by targeting the tubulin component of tumor vessels and thus leads to necrosis. Synonyms: Valecobulin hydrochloride; CKD516 hydrochloride; CKD 516 hydrochloride. CAS No. 1240321-53-2. Molecular formula: C26H29ClN6O5S. Mole weight: 573.07. | |
| CKD-602 | CKD-602 Inhibitor. Uses: Scientific use. Product Category: T7551. CAS No. 213819-48-8. |  |
| CKD-711 | It is produced by the strain of Streptomyces sp. CK-4416. CKD-711 strongly inhibited mammalian α-glucosidase activity, but weakly inhibited mammalian α-amylase from microorganism and mammal, which was similar to acarbose in vivo and in vitro. Synonyms: 4-Deoxy-4-{[(1R,2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)-7-oxabicyclo[4.1.0]hept-2-yl]amino}-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-D-glucopyranose. Molecular formula: C25H43NO20. Mole weight: 677.60. | |
| CKI 7 dihydrochloride | CKI 7 is a CK1 inhibitor, and also inhibits SGK, S6K1 and MSK1. In combination with SB 431542, CKI 7 was shown to induce retinal cell differentiation from human ESCs and iPSCs. Synonyms: CKI-7 dihydrochloride; N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide dihydrochloride. Grade: >98%. CAS No. 1177141-67-1. Molecular formula: C11H14Cl3N3O2S. Mole weight: 358.67. | |
| CKI-7 dihydrochloride | ?98% (HPLC), solid. Group: Fluorescence/luminescence spectroscopy. | |
| CKI-7 free base | CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). Uses: Found to have a potent inhibitory action against casein kinase 1 completely with respect to atp and a much weaker effect on casein kinase 2 and other protein kinases. Synonyms: CKI-7; CKI 7; 8-Isoquinolinesulfonamide, N-(2-aminoethyl)-5-chloro-. Grade: 95%. CAS No. 120615-25-0. Molecular formula: C11H12ClN3O2S. Mole weight: 285.75. | |
| CKI-7 free base | CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC 50 of 6 μM and a K i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK , ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases [1] [2] [3] [4]. Uses: Scientific research. Group: Signaling pathways. CAS No. 120615-25-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-133028. | |
| c-KIT (544-end), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?75% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| c-KIT (544-end, V654A), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| c-KIT (D820E), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| c-Kit-IN-2 | c-Kit-IN-2 is a c-Kit inhibitor with an IC50 of 82 nM, and has good antiproliferative activity against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1 and 2 nM, respectively. Synonyms: 1-(5-Ethyl-1,2-oxazol-3-yl)-3-[4-(2-{[6-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]amino}-1,3-thiazol-5-yl)phenyl]urea; Urea, N-(5-ethyl-3-isoxazolyl)-N'-[4-[2-[[6-(4-ethyl-1-piperazinyl)-4-pyrimidinyl]amino]-5-thiazolyl]phenyl]-. Grade: ≥95%. CAS No. 2121515-37-3. Molecular formula: C25H29N9O2S. Mole weight: 519.62. | |
| c-Kit-IN-3 | c-Kit-IN-3 is a selective inhibitor of c-KIT kinase. c-Kit-IN-3 displays great potencies against most of the gain-of function mutations in the juxtamembrane domain, drugresistant mutations in the ATP binding pocket, and activation loops. Synonyms: c-Kit IN 3; c-Kit IN-3; c-Kit-IN 3. CAS No. 2363169-01-9. Molecular formula: C26H20ClF3N2O4. Mole weight: 516.90. | |
| c-Kit-IN-5-1 | c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1003311-62-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-18302. | |
| c-KIT (N822K), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| c-KIT (T670E), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| c-KIT (T670I), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| c-KIT (Y823D), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CKK-E12 | CKK-E12 is a ionizable lipid in combination with other lipids make up the lipid nanoparticles which are used to deliver RNA-based research. CKK-E12 is highly selective toward liver parenchymal cell in vivo. Uses: Scientific research. Group: Biochemical assay reagents. CAS No. 1432494-65-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-134781. | |
| CL075 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| CL075 | CL075 is a thiazoloquinolone derivative that stimulates TLR8 in human peripheral blood mononuclear cells. Uses: Toll-like receptor agonists. Synonyms: CL 075; CL-075; Thiazolo[4,5-c]quinolin-4-amine, 2-propyl-; 2-Propylthiazolo[4,5-c]quinolin-4-amine; 3M 002; 3M-002; 3M002. Grade: ≥95%. CAS No. 256922-53-9. Molecular formula: C13H13N3S. Mole weight: 243.33. | |
| CL075 | CL075 is a thiazoloquinolone derivative that stimulates TLR8 in human peripheral blood mononuclear cells. It activates NF-κB and triggers preferentially the production of TNF-α and IL-12. CL075 seems also to induce the secretion of IFN-α through TLR7 but to a lesser extend. It induces the activation of NF-κB at 0.4 uM (0.1 ug/ml) in TLR8-transfected HEK293 cells, and ~ 10 times more CL075 is required to activate NF-κB in TLR7-transfected HEK293 cells. Group: Others. Mole weight: 243.33. Stability: Lyophilized product is stable 1 year at -20°C when properly stored. Resuspended CL075 should be aliquoted and stored at -20°C. Resuspended product is stable 6 months at -20°C. Avoid repeated freeze-thaw cycles. Appearance: Yellow lyophilized powder. Storage: Store at -20°C. CL075. Cat No: LIGC-007. |  |
| CL097 | CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages[1]. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production[2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1026249-18-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128799. | |
| CL097 | CL097 is a human TLR7/8 and mouse TLR7 agonist. Synonyms: CL 097; CL-097; 3H-Imidazo[4,5-c]quinolin-4-amine, 2-(ethoxymethyl)-; 2-(Ethoxymethyl)-1H-imidazo[4,5-C]quinolin-4-amine. Grade: ≥95%. CAS No. 1026249-18-2. Molecular formula: C13H14N40. Mole weight: 242.28. | |
| CL 218872 | CL 218872 has been found to be a benzodiazepine agonist and has been found to exhibit anxiolytic and anticonvulsant activities. Synonyms: CL 218872; CL218872; CL-218872; 3-Methyl-6-[-3-(trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine. Grade: ≥99% by HPLC. CAS No. 66548-69-4. Molecular formula: C13H9F3N4. Mole weight: 278.24. | |
| CL 218872 | CL 218872. Group: Biochemicals. Grades: Purified. CAS No. 66548-69-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| CL 218872 | CL 218872 is a selective and orally active benzodiazepine of α1 subunit-containing GABA A receptor with a K i of 130 nM. CL 218872 exerts anxiolytic and anticonvulsant in vivo [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 66548-69-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103505. | |
| CL264 | CL264 is a small-molecule agonist of TLR7. Synonyms: Glycine, N-[4-[[6-amino-2-(butylamino)-7,8-dihydro-8-oxo-9H-purin-9-yl]methyl]benzoyl]-; N-[4-[[6-Amino-2-(butylamino)-7,8-dihydro-8-oxo-9H-purin-9-yl]methyl]benzoyl]glycine; CL 246; CL 264; CL-264; (4-((6-amino-2-(butylamino)-8-oxo-7,8-dihydro-9H-purin-9-yl)methyl)benzoyl)glycine. Grade: ≥95%. CAS No. 1510712-69-2. Molecular formula: C47H73N13O7S. Mole weight: 413.43. | |
| CL2A-SN 38 | CL2A-SN 38 is a drug-linker conjugate for ADC by using SN 38 (a DNA Topoisomerase I inhibitor), linked via CL2A. Synonyms: CL2A-SN-38. CAS No. 1279680-68-0. Molecular formula: C73H97N11O22. Mole weight: 1480.63. | |
Our database is helping our users find suppliers everyday.
